Research Article

Effects of Collagen Antibacterial Functional Dressing plus Continuous Nursing on Lower Extremity Skin Injury Caused by Norepinephrine in Patients with Septic Shock

Xiaoxia Hu,1 Hongxia Wang,2 and Yun Lin1

1Intensive Care Unit, The Third People’s Hospital of Hubei Province, Wuhan 430030, China
2Department of Neurology, The Third People’s Hospital of Hubei Province, Wuhan 430030, China

Correspondence should be addressed to Yun Lin; jiciyun8493136@163.com

Received 31 May 2022; Revised 3 July 2022; Accepted 5 July 2022; Published 18 August 2022

Background. This study was designed to explore the effects of collagen antibacterial functional dressing plus continuous care on norepinephrine-induced lower extremity skin injury in patients with septic shock. Methods. In this prospective, randomized, controlled study, 120 patients with septic shock receiving norepinephrine in our hospital from February 2020 to February 2021 were recruited. All the enrollments were randomized into the experimental group (n = 60) and the control group (n = 60). The control group received continuous care, while the experimental group additionally received collagen antibacterial functional dressing. Outcome measures included skin sensation scores, incidence of lower extremity skin injuries, recovery time, inflammatory factor levels, and care satisfaction. Results. Collagen antibacterial functional dressing plus continuous care resulted in significantly lower skin sensation scores and a lower incidence of skin injuries versus continuous care alone. Patients in the experimental group had faster recovery of lower extremity skin injury than those in the control group. Collagen antibacterial functional dressing plus continuous care was associated with significantly lower levels of inflammatory factors and a higher satisfaction rate than continuous care alone. Conclusion. Collagen antibacterial functional dressing plus continuous care improves the local skin condition of patients with septic shock receiving norepinephrine, regulates the levels of inflammatory factors, reduces the risk of skin injuries, and enhances care satisfaction.

1. Introduction

Septic shock is a clinical syndrome characterized by systemic infection. Metabolic disorders and dysfunctions are frequently seen in most cases, in which the hemodynamic effects, inflammatory factors, and immune factors are mutually influenced, leading to homeostasis imbalance or even multiple organ failure in severe cases. The total mortality rate of septic shock ranges from 40% to 70% [1–3]. In current practice, liquid resuscitation plus vasoactive drugs is a well-recognized protocol for septic shock management. Norepinephrine is a commonly used vasoactive drug in clinical practice [4, 5] that regulates the blood pressure of patients, improves their organ perfusion, and prevents organ functional failure; however, it is highly irritating and may cause skin tissue injuries. Mild injury symptoms include redness, pain, and local tissue necrosis, while severe cases may suffer dysfunction, seriously compromising the treatment effect and the nurse-patient relationship [6, 7]. To this end, comprehensive nursing has been identified for complication prevention of the lower extremities to potentiate the efficacy of norepinephrine; nonetheless, the expected treatment outcome is somehow compromised [8, 9]. Previous studies have found that in the treatment of the skin radiation injury of breast cancer patients during radiotherapy [10, 11], the collagen antibacterial functional dressing accelerated cell metabolism, promoted wound healing, relieved skin pain, and regulated the level of local inflammatory factors, which is conducive to injured skin repair. Accordingly, this study was designed to explore the effectiveness of collagen...
antibacterial functional dressing plus continuous care on the skin injury of lower extremities caused by norepinephrine in patients with septic shock.

2. Materials and Methods

2.1. General Materials. In this prospective, randomized, controlled study, 120 patients with septic shock treated with norepinephrine in our hospital from February 2020 to February 2021 were included. All the enrollments were randomized into the experimental group (n = 60) and the control group (n = 60). This study was approved by the ethical committee of our hospital (No. 2020-15/254).

2.2. Inclusion and Exclusion Criteria

2.2.1. Inclusion Criteria. Inclusion criteria were as follows: (1) patients or their family members were fully informed of the research process and signed the consent form and (2) patients met the diagnostic criteria for septic shock [12] and were treated with norepinephrine.

2.2.2. Exclusion Criteria. Exclusion criteria were as follows: (1) patients with mental problems that prevented normal communication [13]; (2) patients with other organic diseases [14]; and (3) norepinephrine was not included in the treatment plan.

2.2.3. Withdrawal Criteria. Withdrawal criteria were as follows: (1) patients with adverse events or serious adverse events; (2) patients with disease deterioration during the experiment; and (3) patients who revoked their consent.

2.3. Methods

2.3.1. Norepinephrine Therapy. Both groups of patients received an intravenous infusion of norepinephrine (GrandPharma China Co., Ltd., National Medicine Standard H42021301) at the medial malleolus saphenous vein of the lower limbs. The infusion site was altered accordingly in the event of skin injury, and 0.25% procaine was given (Jiangsu Jiuxu Pharmaceutical Co., Ltd., National Medicine Standard H20023101) for partial pain alleviation.

2.3.2. Continuous Care. Both groups of patients were given continuous care. (1) A continuous care exchange group consisting of septic shock patients was established, with the head nurse as the group administrator, and chief physicians were invited to assist the group administration. A continuous care nursing team with two chief physicians, three nurses, a psychologist, and a nutritionist was established to answer the patients’ questions and formulate tailored continuous care protocols. The patients and their families were fully informed of the purpose, process, and significance of the study to ensure proactive and effective participation. (2) The patients in the exchange group were named “Department + Patient Name + Bed Number,” which is convenient for information collection and condition monitoring and documentation. Before discharge, the patients were given disease and care instructions, including knowledge of treatment, nursing, and related complications, and were instructed to correctly perform home care. The following conditions during treatment were documented: (1) sudden increase or decrease of body temperature; (2) impaired consciousness, such as apathy and lethargy; (3) excessive blood pressure fluctuation (an alteration of blood pressure by 15% was considered an excessive fluctuation); and (4) decreased urine output. (3) The patients were informed of the importance of skin management. Patients with septic shock might have flush or clammy skin or have a vascular endometrial injury due to injections of norepinephrine and other drugs, which caused local skin swelling and bruising. (4) Cured cases and proper psychological guidance were introduced to patients to enhance their treatment compliance. (5) The patients were followed up by telephone 3 days after discharge. Then, the telephone follow-up was conducted every 1 month. The duration of follow-up was 3 months.

2.3.3. Collagen Antibacterial Functional Dressing Treatment. The experimental group received collagen antibacterial functional dressing (Tibet Beizhuya Pharmaceutical Co., Ltd., Tibet Naqu Medical Device (2015) No. 1640001) at the norepinephrine injection site. After the injection, with the patients in a sitting position, their skin was cleaned with 37°C water, and the collagen antibacterial dressing was evenly applied to the injection area with a thickness of around 2 mm–3 mm and a diameter of 4 cm around the needlepoint. The dressing was applied once a day before bed. After discharge, the patients were instructed to perform collagen antibacterial functional dressing 3 days later.

2.4. Outcome Measures

2.4.1. Skin Sensation Score. The evaluation is based on the skin toxicity assessment tool [15], and the scale includes
three domains of treatment characteristics, skin reaction, and patient sensation. There are four items in patient sensation, including burning, itching, pressing pain, and stretching. The Riggett five-level scoring method was adopted to investigate the skin sensation scores of patients before and one month after discharge. The higher the score, the more severe the skin injury.

2.4.2. Incidence of Lower Extremity Skin Injury. The drug extravasation and tissue injury during the treatment of patients were meticulously documented. Mild injury includes skin redness, swelling, subcutaneous induration, and pain in the local exudation area, and severe injury includes local tissue necrosis and dysfunction. The number of patients with skin injuries of lower extremities was recorded to calculate the corresponding incidence.

2.4.3. Recovery Time of Lower Extremity Skin Injury. The recovery time of the patient’s lower extremity skin injury was recorded.

2.4.4. Inflammatory Factor Level. 5 ml of morning fasting venous blood was collected from the patients before treatment and 1 month after discharge, and the immunoturbidimetric method was used (kit: Nanjing Getein Biotech Co., Ltd., Su Food and Drug Administration Approval Number 2012 No. 2400146) to determine the levels of C-reactive protein (CRP), serum procalcitonin (PCT), and tumor necrosis factor-alpha (TNF-α), and the operation process was carried out in strict accordance with the kit instructions.

2.4.5. Care Satisfaction. The hospital’s self-developed scale was used to evaluate patients’ care satisfaction. The scale has a maximum score of 5 points, with 5 points for highly satisfied, 3-4 points for satisfied, and 2 points and below for dissatisfied. The satisfaction rate 1 month after discharge was calculated.

2.5. Statistical Analysis. The selected data processing software for this study was SPSS 20.0, and the graphics were plotted by using GraphPad Prism 7 (GraphPad Software, San Diego, USA). The research included count data and measurement data. The count data were analyzed by the chi-square test, and the measurement data were analyzed by the t-test. $P < 0.05$ indicates that the difference is statistically significant.

### Table 2: Comparison of skin sensation scores ($x \pm s$, points).

|         | Burning | Itchiness | Stretching | Stinging |
|---------|---------|-----------|------------|----------|
|         | Before 1 month after | Before 1 month after | Before 1 month after | Before 1 month after |
| Experimental group | 0.60 ± 0.08 | 0.34 ± 0.02 | 0.79 ± 0.06 | 0.45 ± 0.04 |
| Control group | 0.74 ± 0.05 | 0.49 ± 0.05 | 0.90 ± 0.08 | 0.65 ± 0.06 |
| $t$       | 11.50   | 21.58     | 8.52       | 21.48     |
| $P$       | <0.001  | <0.001    | <0.001     | <0.001    |

### Table 3: Comparison of the incidence rate of skin injury of the lower extremities.

| n | Skin injury | No skin injury |
|---|-------------|----------------|
| Experimental group | 60 | 3 | 57 |
| Control group | 60 | 14 | 46 |
| $\chi^2$ | 8.292 |
| $P$ | 0.004 |

Figure 1: Comparison of recovery time of patients with lower extremity skin injury, **P < 0.001.

### 3. Results

3.1. Patient Characteristics. The patient characteristics of the two groups were comparable ($P > 0.05$) (Table 1).

3.2. Comparison of Skin Sensation Scores of Patients. Collagen antibacterial functional dressing plus continuous care resulted in significantly lower skin sensation scores versus continuous care alone ($P < 0.001$), as shown in Table 2.

3.3. Comparison of the Incidence Rate of Skin Injury of the Lower Extremities. A lower incidence of lower limb skin injury in the experimental group was observed ($P < 0.05$), as shown in Table 3.

3.4. Comparison of Recovery Time of Patients with Lower Extremity Skin Injury. Patients in the experimental group had faster recovery of lower extremity skin injury than those in the control group ($P < 0.001$) (Figure 1).
The results showed that the skin sensation scores and the incidence rate of skin injuries of the experimental group were significantly lower than those of the control group. Pathogenic microorganisms and cell wall products invading the blood circulation during septic shock result in activation of cellular and the humoral immune system, and various endogenous mediators act in the organs and systems, leading to metabolic disorders and even multiple organ failure [16]. In the pathogenesis of septic shock, inflammatory factors are the most important factors that induce hemodynamic alterations and may lead to systemic vasodilation [17] and reduced organ perfusion. Therefore, proper hemodynamic management is key to avoid multiple organ failures [18]. At present, vasoactive drugs are administered for tissue perfusion restoration [19], in which norepinephrine is the most common one for septic shock. Norepinephrine effectively constricts blood vessels, increases arterial blood pressure, and averts internal organ injury. However, norepinephrine has strong penetrability and is prone to drug extravasation, causing vascular smooth muscle spasm, vascular intima damage, and endometritis [20]. Previously, comprehensive care has been recommended for septic shock management to avoid complications secondary to norepinephrine [21] but failed to achieve the expected outcome. In the present study, the incidence of lower extremity skin injury in the experimental group was significantly lower than that in the control group, which may be attributed to the intense antibacterial effects of collagen stock solution, hydrogel, and polylysine in the collagen antibacterial functional dressing [22]. The research of Wunsch et al. showed that collagen antibacterial functional dressing enhanced the phagocytic function of wound macrophages and reduced the inflammatory response of patients with breast cancer [23].

In addition, the experimental group has significantly lower levels of inflammatory factors after discharge, indicating that the collagen antibacterial functional dressing yields strong local anti-inflammatory and moisturizing effects to boost the growth of epidermal cells and promote metabolism.

The current study found that the skin-tingling sensation score of the patient was slightly lower in the experimental group. The reason may be ascribed to the individual differences between the patients. Also, continuous care ensured a high home care quality and resulted in a better recovery of the patients in the experimental group. A prior study has revealed that collagen antibacterial functional dressing contributed to the repair of skin defects in diabetic patients and promoted vascular regeneration [24]. Thus, collagen antibacterial functional dressing could also accelerate wound repair and reduce the pain of the patient with lower extremity skin injuries. Kasugai et al. treated patients with septic shock with collagen antibacterial functional dressing and compared them with Kanghuier’s enhanced transparent paste. It was found that collagen antibacterial functional dressing facilitated vascular regeneration, reduced local edema, and relieved the stimulation of peripheral nerves by active factors after drug extravasation [25].

5. Conclusions
Collagen antibacterial functional dressing plus continuous care improves the local skin condition of patients with septic shock receiving norepinephrine, regulates the levels of inflammatory factors, reduces the risk of skin injuries, and enhances care satisfaction.

Data Availability
The data can be obtained from the corresponding author upon reasonable request.

Table 4: Comparison of the levels of inflammatory factors (\(\bar{x} \pm s\)).

|                | CRP (mg/L) Before | CRP (mg/L) 1 month after | PCT (ng/L) Before | PCT (ng/L) 1 month after | TNF-\(\alpha\) (pg/mL) Before | TNF-\(\alpha\) (pg/mL) 1 month after |
|----------------|-------------------|--------------------------|-------------------|--------------------------|-----------------------------|----------------------------------|
| **Experimental group** | 172.65 ± 24.11    | 10.20 ± 1.21             | 25.56 ± 3.21      | 1.01 ± 0.25              | 20.12 ± 2.65                | 3.58 ± 1.20                      |
| **Control group**    | 172.56 ± 25.13    | 13.58 ± 2.23             | 26.14 ± 3.20      | 1.45 ± 0.30              | 20.23 ± 2.10                | 5.24 ± 2.15                      |
| \(t\)               | 0.006             | 2.503                    | 0.285             | 2.354                    | 0.079                       | 1.273                            |
| \(P\)               | 0.996             | 0.024                    | 0.778             | 0.033                    | 0.938                       | 0.222                            |

Table 5: Comparison of care satisfaction rate (n (%)).

|                | n    | Highly satisfied | Satisfied | Dissatisfied | Satisfaction rate |
|----------------|------|------------------|-----------|--------------|-------------------|
| **Experimental group** | 60   | 30 (50.0)        | 28 (46.7) | 2 (3.3)      | 58 (96.7)         |
| **Control group**    | 60   | 18 (30.0)        | 30 (50.0) | 12 (20.0)    | 48 (80.0)         |
| \(\chi^2\)         |      |                  |           |              | 8.086             |
| \(P\)              |      |                  |           |              | 0.004             |
Ethical Approval
This study was approved by the Third People’s Hospital of Hubei Province ethics committee.

Consent
The patients or their family members were fully informed of the research process and signed the consent form.

Conflicts of Interest
The authors declare that there are no commercial or financial relationships that could be construed as potential conflicts of interest.

Authors’ Contributions
Xiaoxia Hu designed the study. Hongxia Wang performed the experiments and collected and analyzed the data. Yun Lin wrote the manuscript.

References
[1] Q. Habes, L. V. Ede, J. Gerretsen, M. Kox, and P. Pickkers, “Norepinephrine contributes to enterocyte injury in septic shock patients: a prospective cohort study,” Shock, vol. 49, p. 1, 2018.
[2] H. Yamamura, Y. Kawazoe, K. Miyamoto, T. Yamamoto, Y. Ohta, and T. Morimoto, “Effect of norepinephrine dosage on mortality in patients with septic shock,” Journal of Intensive Care, vol. 6, no. 1, p. 12, 2018.
[3] R. Domizi, S. Calcinaro, S. Harris et al., “Relationship between norepinephrine dose, tachycardia and outcome in septic shock: a multicentre evaluation,” Journal of Critical Care, vol. 57, pp. 185–190, 2020.
[4] H. A. Raza, A. Arshad, A. Ayaz et al., “Vasopressin in conjunction with norepinephrine in septic shock: a retrospective cohort study from a low middle-income country,” Critical Care Explorations, vol. 2, 2020.
[5] L. Santoriello, K. Schweiger, D. Aronowitz et al., “Effect of phenylephrine versus norepinephrine on 28-day mortality and SICU length of stay in septic shock,” International Journal of Surgery: Globalization and Health, vol. 3, no. 4, p. e19, 2020.
[6] F. Uhel and T. Poll, “Norepinephrine in septic shock: a mixed blessing,” American Journal of Respiratory and Critical Care Medicine, vol. 202, 2020.
[7] H. W. He, W. L. Liu, X. Zhou, Y. Long, and D. W. Liu, “Effect of mean arterial pressure change by norepinephrine on peripheral perfusion index in septic shock patients after early resuscitation,” Chinese Medical Journal, vol. 133, 2020.
[8] J. Mårtensson and A. C. Gordon, “Terlipressin or norepinephrine, or both in septic shock?,” Intensive Care Medicine, vol. 44, no. 11, pp. 1964–1966, 2018.
[9] K. Dalla, O. Bech-Hanssen, and S. Ricksten, “Impact of norepinephrine on right ventricular afterload and function in septic shock—a strain echocardiography study,” Acta Anaesthesiologica Scandinavica, vol. 63, no. 10, pp. 1337–1345, 2019.
[10] T. G. Kampmeier, P. H. Arnemann, M. Hessler et al., “Comparison of first-line and second-line terlipressin versus sole norepinephrine in fulminant ovine septic shock,” Scientific Reports, vol. 8, no. 1, p. 7105, 2018.
[11] N. Musallam, D. Altshuler, C. Merchan, B. Zakhary, C. Aberle, and J. Papadopoulos, “Evaluating vasopressor discontinuation strategies in patients with septic shock on concomitant norepinephrine and vasopressin infusions,” The Annals of Pharmacotherapy, vol. 52, no. 8, pp. 733–739, 2018.
[12] T. Scheeren, J. Bakker, D. D. Backer et al., “Current use of vasopressors in septic shock,” ULB Institutional Repository, vol. 9, 2019.
[13] M. A. Elbouhy, M. Soliman, A. Gaber, K. M. Taema, and A. Abdel-Aziz, “Early use of norepinephrine improves survival in septic shock: earlier than early,” Archives of Medical Research, vol. 50, no. 6, pp. 325–332, 2019.
[14] T. W. Jones, H. Azimi, C. Scott, and A. S. Newsome, “Does norepinephrine exhibit a time-dose relationship in septic shock?” Critical Care Medicine, vol. 49, no. 3, pp. e345–e346, 2021.
[15] J. A. Russell, A. C. Gordon, and K. R. Walley, “Early may be better: early low-dose norepinephrine in septic shock,” American Journal of Respiratory and Critical Care Medicine, vol. 199, no. 9, pp. 1049–1051, 2019.
[16] A. Dargent, L. Quintin, M. Jacquier, I. Fournel, and J. P. Quenot, “Vasopressor for refractory septic shock: dexmedetomidine could help decrease norepinephrine requirements,” Minerva Anestesiologica, vol. 86, no. 8, pp. 885-886, 2020.
[17] S. Fukuda, K. Ihara, C. R. Andersen et al., “Modulation of peroxynitrite reduces norepinephrine requirements in ovine MRSA septic shock,” Shock, vol. 52, no. 5, pp. e92–e99, 2019.
[18] E. D. Wieruszewski, G. M. Jones, M. J. Samarín, and L. A. Kimmons, “Predictors of dysrhythmias with norepinephrine use in septic shock,” Journal of Critical Care, vol. 61, pp. 133–137, 2021.
[19] A. Messina, A. Milani, E. Morenghi et al., “Norepinephrine infusion in the emergency department in septic shock patients: a retrospective 2-years safety report and outcome analysis,” International Journal of Environmental Research and Public Health, vol. 18, no. 2, p. 824, 2021.
[20] M. Haiduc, S. Radparvar, S. L. Aitken, and J. Altshuler, “Does switching norepinephrine to phenylephrine in septic shock complicated by atrial fibrillation with rapid ventricular response improve time to rate control,” Journal of Intensive Care Medicine, vol. 36, no. 2, pp. 191–196, 2020.
[21] D. A. Hammond, G. L. Sacha, B. D. Bissell et al., “Effects of norepinephrine and vasopressin discontinuation order in the recovery phase of septic shock: a systematic review and individual patient data meta-analysis,” Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, vol. 39, no. 5, pp. 544–552, 2019.
[22] J. Morgenstern, “News: early norepinephrine has potential for septic shock,” Emergency Medicine News, vol. 41, 2019.
[23] H. Wunsch, M. Hua, A. J. Walkey, G. Rubenfeld, E. Vail, and H. B. Gershengorn, “Evaluation of Practice Changes in the Care of Patients with Septic Shock during the U.S. Norepinephrine Shortage,” Annals of the American Thoracic Society, vol. 15, 2018.
[24] A. Morelli, F. Sanfilippo, P. Arnemann et al., “The effect of propofol and dexmedetomidine sedation on norepinephrine requirements in septic shock patients: a crossover trial,” Critical Care Medicine, vol. 47, no. 2, p. 1, 2018.
[25] D. Kasugai, A. Hirakawa, M. Ozaki et al., “Maximum norepinephrine dosage within 24 hours as an indicator of refractory septic shock: a retrospective study,” Journal of Intensive Care Medicine, vol. 35, no. 11, pp. 1285–1289, 2019.